Antigen discovery for transmission-blocking vaccines in Plasmodium vivax

Information

  • Research Project
  • 9933487
  • ApplicationId
    9933487
  • Core Project Number
    R01AI150533
  • Full Project Number
    1R01AI150533-01
  • Serial Number
    150533
  • FOA Number
    PAR-17-142
  • Sub Project Id
  • Project Start Date
    4/6/2020 - 4 years ago
  • Project End Date
    3/31/2025 - 9 months from now
  • Program Officer Name
    MO, ANNIE X Y
  • Budget Start Date
    4/6/2020 - 4 years ago
  • Budget End Date
    3/31/2021 - 3 years ago
  • Fiscal Year
    2020
  • Support Year
    01
  • Suffix
  • Award Notice Date
    4/6/2020 - 4 years ago
Organizations

Antigen discovery for transmission-blocking vaccines in Plasmodium vivax

Project Summary For the immense undertaking by many malaria-endemic nations to eliminate malaria, interruption of malaria transmission has been recognized as one of the greatest challenges, which requires integrated approaches. Plasmodium vivax, the most geographically widespread human malaria, is more resilient to conventional malaria control measures due to its intrinsic biology such as hypnozoite formation responsible for relapses and earlier gametocyte development enabling transmission before manifestation of symptoms. Transmission- blocking vaccines (TBVs) are a promising strategy especially suited for the task of elimination of vivax malaria. However, the progress in TBV development has been very slow, whereas TBV research for P. vivax lags even far behind that for Plasmodium falciparum. With only five parasite antigens as the top TBV candidates, concerted efforts to identify new TBV antigens are urgently needed. In this application, we propose to use an innovative antigen discovery pathway taking advantage of new protein expression and immunoscreening technologies, and advancement in vaccine design and delivery platforms. We aim to 1) discover new sexual- stage antigens by in silico prediction and immunoscreening, and evaluate their transmission reducing activities in Plasmodium berghei; 2) evaluate a TBV combination strategy targeting both pre- and post-fertilization antigens; and 3) assess the transmission reducing activities of new TBV candidates for P. vivax using transgenic P. berghei and clinical P. vivax isolates. Results from these comprehensive studies will contribute to a better understanding of sexual development in malaria parasites and identification of new sexual-stage antigens for the TBV development pipeline.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R01
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
    127000
  • Indirect Cost Amount
    10000
  • Total Cost
    137000
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:137000\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CHINA MEDICAL UNIVERSITY
  • Organization Department
  • Organization DUNS
    529786253
  • Organization City
    SHENYANG
  • Organization State
  • Organization Country
    CHINA
  • Organization Zip Code
    110122
  • Organization District
    CHINA